PapersFlow Research Brief
Eosinophilic Disorders and Syndromes
Research Guide
What is Eosinophilic Disorders and Syndromes?
Eosinophilic disorders and syndromes are a cluster of conditions characterized by hypereosinophilic syndrome and related disorders, involving sustained eosinophilia, molecular pathogenesis such as fusion genes like FIP1L1-PDGFRA, cardiac manifestations, and therapeutic management with agents like imatinib mesylate.
This field encompasses 37,340 works on the classification, molecular pathogenesis, and treatment of eosinophilic disorders. Key topics include fusion genes such as FIP1L1-PDGFRA and the use of imatinib mesylate for therapeutic management. Research addresses cardiac manifestations and precise classification of these syndromes.
Topic Hierarchy
Research Sub-Topics
FIP1L1-PDGFRA Fusion in Hypereosinophilic Syndrome
This sub-topic examines the molecular detection, functional consequences, and prognostic significance of the FIP1L1-PDGFRA fusion gene in patients with hypereosinophilic syndrome. Researchers study its role in driving eosinophil proliferation and its implications for targeted therapies.
Imatinib Mesylate Treatment for PDGFRA-Associated Eosinophilia
This area investigates the efficacy, resistance mechanisms, and long-term outcomes of imatinib mesylate in treating PDGFRA-rearranged eosinophilic disorders. Studies focus on dosing regimens, response predictors, and combination therapies.
Cardiac Manifestations in Hypereosinophilic Syndrome
Researchers explore eosinophil-mediated endomyocardial damage, diagnostic imaging, and therapeutic interventions for cardiac involvement in hypereosinophilic syndrome. This includes histopathological studies and risk stratification models.
Classification of Eosinophilic Disorders
This sub-topic covers updated WHO classifications, clinicopathologic criteria, and molecular subtyping of idiopathic, clonal, and reactive eosinophilic disorders. Researchers develop diagnostic algorithms integrating genetics and cytology.
Molecular Pathogenesis of Idiopathic Hypereosinophilia
Studies investigate cytokine dysregulation, eosinophil activation pathways, and novel genetic drivers in idiopathic hypereosinophilic syndrome excluding known fusions. Research includes omics profiling and signaling pathway analyses.
Why It Matters
Eosinophilic disorders impact patients through organ damage from persistent eosinophilia, with imatinib mesylate targeting fusion genes like FIP1L1-PDGFRA to achieve hematologic responses. In chronic myeloid leukemia, a related myeloproliferative condition with eosinophilic features, imatinib demonstrated superiority over interferon alfa plus low-dose cytarabine, yielding higher hematologic and cytogenetic responses and lower progression rates (O’Brien et al. (2003) in "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia"). Five-year follow-up showed durable responses in a high proportion of chronic-phase CML patients on continuous imatinib (Druker et al. (2006) in "Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia"). These findings support targeted tyrosine kinase inhibition in eosinophil-driven pathologies, reducing mortality and improving survival.
Reading Guide
Where to Start
"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells" (1996) by Druker et al., as it establishes the mechanism of tyrosine kinase inhibition foundational to treatments like imatinib for PDGFRA-driven eosinophilic disorders.
Key Papers Explained
Druker et al. (1996) in "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells" introduced selective Abl kinase inhibition, which O’Brien et al. (2003) in "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" applied clinically to show imatinib's superiority in CML with eosinophilic overlaps; Druker et al. (2006) in "Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia" then confirmed long-term durability, informing eosinophilic syndrome management.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize molecular classification of hypereosinophilic syndrome subtypes responsive to imatinib, with focus on PDGFRA fusion detection; no recent preprints available, but ongoing needs include biomarkers for cardiac risk stratification.
Papers at a Glance
Frequently Asked Questions
What are the main molecular drivers in eosinophilic disorders?
Fusion genes such as FIP1L1-PDGFRA represent key molecular drivers in hypereosinophilic syndrome. These genetic alterations contribute to sustained eosinophilia and organ involvement. Targeted therapies like imatinib mesylate inhibit the associated tyrosine kinase activity.
How does imatinib mesylate treat eosinophilic disorders?
Imatinib mesylate acts as a selective inhibitor of tyrosine kinases, including those activated by fusion genes in eosinophilic conditions. It induces hematologic and cytogenetic responses in patients with PDGFRA rearrangements. Long-term use sustains durable responses with an acceptable safety profile.
What cardiac manifestations occur in eosinophilic syndromes?
Cardiac manifestations in eosinophilic disorders include endomyocardial fibrosis and thrombosis due to eosinophil-mediated damage. These complications arise from persistent eosinophilia. Early therapeutic intervention with kinase inhibitors can mitigate progression.
What is the classification of eosinophilic disorders?
Classification of eosinophilic disorders distinguishes idiopathic hypereosinophilic syndrome from clonal variants driven by fusion genes like FIP1L1-PDGFRA. Myeloproliferative subtypes overlap with conditions responsive to imatinib. Accurate classification guides targeted therapy selection.
What role do tyrosine kinase inhibitors play in management?
Tyrosine kinase inhibitors like imatinib target aberrant signaling in eosinophilic disorders with PDGFRA fusions. Druker et al. (1996) in "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells" demonstrated growth inhibition in kinase-driven cells. This approach extends to eosinophil-related pathologies for clinical benefit.
Open Research Questions
- ? How do FIP1L1-PDGFRA fusion genes precisely contribute to cardiac damage in hypereosinophilic syndrome?
- ? What criteria best classify idiopathic versus clonal eosinophilic disorders for imatinib responsiveness?
- ? Can imatinib mesylate dosing be optimized to prevent long-term cardiac manifestations?
- ? Which additional fusion genes beyond PDGFRA drive refractory eosinophilia?
Recent Trends
The field includes 37,340 works with emphasis on imatinib mesylate for PDGFRA-associated eosinophilia, as shown in durable CML responses by Druker et al. ; no growth rate data or recent preprints/news indicate stable research volume centered on therapeutic management and classification.
2006Research Eosinophilic Disorders and Syndromes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Eosinophilic Disorders and Syndromes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers